These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 39097431)
1. Cardiovascular toxicity in antitumor therapy: biological and therapeutic insights. Lin X; Ma X; Zhao S; Yao J; Han L; Jing Y; Xue X Trends Cancer; 2024 Oct; 10(10):920-934. PubMed ID: 39097431 [TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Toxicity in Cancer Therapy: Protecting the Heart while Combating Cancer. Manhas A; Tripathi D; Thomas D; Sayed N Curr Cardiol Rep; 2024 Sep; 26(9):953-971. PubMed ID: 39042344 [TBL] [Abstract][Full Text] [Related]
3. Mechanisms of Cardiovascular Toxicities Induced by Cancer Therapies and Promising Biomarkers for Their Prediction: A Scoping Review. Yan T; Yu H; Li T; Dong Y Heart Lung Circ; 2024 May; 33(5):605-638. PubMed ID: 38242833 [TBL] [Abstract][Full Text] [Related]
4. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. Totzeck M; Schuler M; Stuschke M; Heusch G; Rassaf T Int J Cardiol; 2019 Apr; 280():163-175. PubMed ID: 30661849 [TBL] [Abstract][Full Text] [Related]
5. Statins in Mitigating Anticancer Treatment-Related Cardiovascular Disease. Jiang R; Lou L; Shi W; Chen Y; Fu Z; Liu S; Sok T; Li Z; Zhang X; Yang J Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337662 [TBL] [Abstract][Full Text] [Related]
6. Cardio-oncology Part I: chemotherapy and cardiovascular toxicity. O'Hare M; Sharma A; Murphy K; Mookadam F; Lee H Expert Rev Cardiovasc Ther; 2015 May; 13(5):511-8. PubMed ID: 25843285 [TBL] [Abstract][Full Text] [Related]
7. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Zamorano JL; Lancellotti P; Rodriguez Muñoz D; Aboyans V; Asteggiano R; Galderisi M; Habib G; Lenihan DJ; Lip GYH; Lyon AR; Lopez Fernandez T; Mohty D; Piepoli MF; Tamargo J; Torbicki A; Suter TM; Eur Heart J; 2016 Sep; 37(36):2768-2801. PubMed ID: 27567406 [No Abstract] [Full Text] [Related]
8. Pediatric Cardio-Oncology: Development of Cancer Treatment-Related Cardiotoxicity and the Therapeutic Approach to Affected Patients. Ryan TD; Nagarajan R; Godown J Curr Treat Options Oncol; 2019 May; 20(7):56. PubMed ID: 31129800 [TBL] [Abstract][Full Text] [Related]
9. Cardiovascular Toxicity and Risk Mitigation with Lung Cancer Treatment. Yegya-Raman N; Berlin E; Feigenberg SJ; Ky B; Sun L Curr Oncol Rep; 2023 May; 25(5):433-444. PubMed ID: 36811807 [TBL] [Abstract][Full Text] [Related]
10. SEOM clinical guidelines on cardiovascular toxicity (2018). Virizuela JA; García AM; de Las Peñas R; Santaballa A; Andrés R; Beato C; de la Cruz S; Gavilá J; González-Santiago S; Fernández TL Clin Transl Oncol; 2019 Jan; 21(1):94-105. PubMed ID: 30627982 [TBL] [Abstract][Full Text] [Related]
11. [Cardiotoxicity of anticancer therapies. Towards the implementation of cardio-oncology units]. Hameau R; Gabrielli L; Garrido M; Guzmán AM; Retamal I; Vacarezza MJ; Greig D; Ocqueteau M; Sánchez C; Pizarro M; Corvalán A; Lavandero S; Castro PF; Martínez G Rev Med Chil; 2018 Jan; 146(1):68-77. PubMed ID: 29806680 [TBL] [Abstract][Full Text] [Related]
12. Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy. Virani SA; Dent S; Brezden-Masley C; Clarke B; Davis MK; Jassal DS; Johnson C; Lemieux J; Paterson I; Sebag IA; Simmons C; Sulpher J; Thain K; Thavendiranathan P; Wentzell JR; Wurtele N; Côté MA; Fine NM; Haddad H; Hayley BD; Hopkins S; Joy AA; Rayson D; Stadnick E; Straatman L Can J Cardiol; 2016 Jul; 32(7):831-41. PubMed ID: 27343741 [TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomics for immunotherapy and immune-related cardiotoxicity. Castrillon JA; Eng C; Cheng F Hum Mol Genet; 2020 Oct; 29(R2):R186-R196. PubMed ID: 32620943 [TBL] [Abstract][Full Text] [Related]
14. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Pennock GK; Chow LQ Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281 [TBL] [Abstract][Full Text] [Related]
15. From cardio-oncology to cardio-onco-pharmacology: Towards a multidisciplinary approach in the understanding and management of cardiotoxicity. Ederhy S; Devos P; Cohen A; Pinna B; Bretagne M; Nguyen LS; Salem JE Therapie; 2022; 77(2):197-206. PubMed ID: 34895759 [TBL] [Abstract][Full Text] [Related]
16. Cardiotoxicities of novel cancer immunotherapies. Stein-Merlob AF; Rothberg MV; Ribas A; Yang EH Heart; 2021 Nov; 107(21):1694-1703. PubMed ID: 33722826 [TBL] [Abstract][Full Text] [Related]
17. Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology. Rassaf T; Totzeck M; Backs J; Bokemeyer C; Hallek M; Hilfiker-Kleiner D; Hochhaus A; Lüftner D; Müller OJ; Neudorf U; Pfister R; von Haehling S; Lehmann LH; Bauersachs J; Clin Res Cardiol; 2020 Oct; 109(10):1197-1222. PubMed ID: 32405737 [TBL] [Abstract][Full Text] [Related]
18. Cardiovascular Toxicities in Pediatric Cancer Survivors. Ryan TD; Nagarajan R; Godown J Cardiol Clin; 2019 Nov; 37(4):533-544. PubMed ID: 31587793 [TBL] [Abstract][Full Text] [Related]
19. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165 [TBL] [Abstract][Full Text] [Related]